New HIV-vaccine tested on peopleFebruary 14, 2012
Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers. The participants were so to say vaccinated with their own cells. The researchers filtered certain white blood cells out of the volunteer's blood, 'loaded' them outside the body and then gave them back. The immune system of the testees was better than before in attacking and suppressing the virus, the scientists reported in the top journal AIDS. But they still cannot cure the disease.
Actually, medical science can control an HIV-infection quite well, with a medicine cocktail. 'Seropositive' people (people who are infected with the HIV virus) now can lead a reasonably normal life, but their virus is not exterminated. When they stop the treatment it immediately rebounds.
Science knows what the problem is: the 'special forces' in our blood (the CD8 cells, in medical lingo) get not enough support from the general staff (the dendritic cells, that show the combat units what to attack). Dendritic cells exhibit on their exterior typical parts of the virus to be attacked. But human dendritic cells are not that good in getting the right information on the HIV virus and to transform it into good examples for the CD8 battle cells.
The virologists and HIV-physicians of the Institute of Tropical Medicine and the haematologists of Antwerp University Hospital have cooperated for years on that problem. Together they succeeded to 'load' dendritic cells of seropositive volunteers in the lab with the building instructions (genetic information in the form of so-called messenger RNA) for HIV proteins. They could make the dendritic cells to execute the instructions and to exhibit the resulting typical part of the HIV virus on their surface. Subsequent research in test tubes demonstrated that the 'loaded' dendritic cells were able to activate battle cells.
Time had come to proceed to humans. Flemish, Belgian and French research foundations provided grants. Six seropositive persons who for a long time already used the drug cocktails, were prepared to volunteer. The scientists filtered the dendritic cells from a large volume of their blood, cultivated them in test tubes in the cell-therapy unit of the Antwerp University Hospital and provided them with the genetic instructions of an HIV virus. They then froze the loaded cells.
The volunteers received four times, with four-week intervals, a small quantity of their own reworked dendritic cells. And indeed, after each vaccination the CD8 battle cells in their bodies recognised the virus better and better, while the vaccination had virtually no side effects. The most important result was that the vaccine-activated battle cells became better and better in suppressing the virus, in test tubes for the moment. But HIV remains a disguise artist; it still succeeds in changing its proteins sufficiently fast and often to let at least a few viruses escape the attack.
So it remains impossible to cure AIDS, but the results are encouraging: the vaccine, made of the participant's own dendritic cells, is safe and has some therapeutic effect, be it a limited one. But sufficiently strong for a publication in the most renowned journal for HIV researchers, AIDS. And more than sufficient to enthuse and motivate the Antwerp scientists.
Institute of Tropical Medicine Antwerp
Related HIV Vaccine Current Events and HIV Vaccine News Articles
Telephone-based cognitive behavioral therapy significantly improves menopause symptoms
Chatting on the phone with a "sleep coach" and keeping a nightly sleep diary significantly improve sleep quality and reduce insomnia in women through all stages of menopause, according to a new study published today in JAMA Internal Medicine.
HIV vaccine design should adapt as HIV virus mutates
Human immunodeficiency virus is known to be a highly variable virus that adapts to a person's immune response during the lifetime infection, and a new study published in Nature Medicine shows that viral adaptation in HIV can predict a person's current disease status, as well as the degree to which newly transmitted HIV-1 is adapted to their new host.
Precision prevention of colorectal cancer
Precision medicine's public face is that of disease -- and better treatments for that disease through targeted therapies.
Findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial
Some people infected with HIV naturally produce antibodies that effectively neutralize many strains of the rapidly mutating virus, and scientists are working to develop a vaccine capable of inducing such "broadly neutralizing" antibodies that can prevent HIV infection.
Progress toward an HIV cure highlighted in special issue of AIDS Research and Human Retroviruses
A cure for HIV/AIDS is the ultimate goal of rapidly advancing research involving diverse and innovative approaches.
Obesity and weight gain in HIV-infected adults on antiretroviral therapy: What's the harm?
The percentage of HIV-infected adults who were obese-body mass index >30 kg/m2-when they began antiretroviral therapy (ART) doubled over a 12-year period.
Fred Hutch endorses HPV vaccination for cancer prevention
In response to low national vaccination rates for the human papillomavirus, or HPV, Fred Hutchinson Cancer Research Center has joined with the 68 other U.S. National Cancer Institute-designated cancer centers in issuing a statement urging for increased vaccination in adolescent girls and boys for the prevention of many types of HPV-related cancers in adulthood.
In pursuit of HIV vaccine, TSRI scientists shed light on antibody origins
From Peter Parker's fateful spider bite to Arthur pulling the sword from the stone at the beginning of his reign--everyone likes to know a hero's origin story.
Have sex workers revealed a connection between semen exposure and HIV resistance?
More than half of all people infected by the HIV-1 virus worldwide are women. Commercial sex workers, who are at increased risk of contracting HIV because of repeated exposure to the virus, have long been studied to test preventive behavioral and vaccine approaches aimed at decreasing the number of infections.
Progress toward preventing HIV highlighted in special issue of AIDS research and human retroviruses
New and emerging biomedical pre-exposure prophylaxis (PrEP) approaches to prevent HIV infection in targeted high-risk populations offer the most effective near-term strategy to reduce HIV transmission.
More HIV Vaccine Current Events and HIV Vaccine News Articles